OncologyOnline.net

Oncology Xagena

Xagena Mappa
Xagena Newsletter
OncologiaMedica.net
Medical Meeting

Search results for "Lorlatinib"

Final, mature progression-free survival ( PFS ) from the global phase III ALEX study of Alectinib ( Alecensa ) vs Crizotinib ( Xalkori ) in untreated, advanced / metastatic anaplastic lymphoma kinase- ...


Lorlatinib ( Lorviqua ) is a 3rd-generation ALK tyrosine kinase inhibitor ( TKI ) developed to penetrate the central nervous system ( CNS ) and overcome resistance to 2nd-generation ( 2nd-gen ) ALK TK ...